These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 17283164

  • 1. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.
    Jazirehi AR, Vega MI, Bonavida B.
    Cancer Res; 2007 Feb 01; 67(3):1270-81. PubMed ID: 17283164
    [Abstract] [Full Text] [Related]

  • 2. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR, Bonavida B.
    Oncogene; 2005 Mar 24; 24(13):2121-43. PubMed ID: 15789036
    [Abstract] [Full Text] [Related]

  • 3. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.
    Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B.
    Cancer Res; 2005 Jan 01; 65(1):264-76. PubMed ID: 15665303
    [Abstract] [Full Text] [Related]

  • 4. Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy.
    Jazirehi AR, Bonavida B.
    Methods Mol Biol; 2011 Jan 01; 731():407-19. PubMed ID: 21516425
    [Abstract] [Full Text] [Related]

  • 5. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions.
    Bonavida B.
    Oncogene; 2007 May 28; 26(25):3629-36. PubMed ID: 17530016
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
    Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B.
    Cancer Res; 2004 Oct 01; 64(19):7117-26. PubMed ID: 15466208
    [Abstract] [Full Text] [Related]

  • 7. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma.
    Bonavida B, Vega MI.
    Drug Resist Updat; 2005 Oct 01; 8(1-2):27-41. PubMed ID: 15939340
    [Abstract] [Full Text] [Related]

  • 8. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.
    Vega MI, Huerta-Yepaz S, Garban H, Jazirehi A, Emmanouilides C, Bonavida B.
    Oncogene; 2004 Apr 29; 23(20):3530-40. PubMed ID: 15077178
    [Abstract] [Full Text] [Related]

  • 9. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.
    Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS.
    Clin Cancer Res; 2008 Mar 01; 14(5):1550-60. PubMed ID: 18316580
    [Abstract] [Full Text] [Related]

  • 10. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways.
    Mathas S, Rickers A, Bommert K, Dörken B, Mapara MY.
    Cancer Res; 2000 Dec 15; 60(24):7170-6. PubMed ID: 11156427
    [Abstract] [Full Text] [Related]

  • 11. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions.
    Vega MI, Huerta-Yepez S, Martinez-Paniagua M, Martinez-Miguel B, Hernandez-Pando R, González-Bonilla CR, Chinn P, Hanna N, Hariharan K, Jazirehi AR, Bonavida B.
    Clin Cancer Res; 2009 Nov 01; 15(21):6582-94. PubMed ID: 19861448
    [Abstract] [Full Text] [Related]

  • 12. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E.
    Haematologica; 2002 Jan 01; 87(1):33-43. PubMed ID: 11801463
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.
    Alas S, Emmanouilides C, Bonavida B.
    Clin Cancer Res; 2001 Mar 01; 7(3):709-23. PubMed ID: 11297268
    [Abstract] [Full Text] [Related]

  • 14. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.
    Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, Knight J, Starostik P, Deans J, Hernandez-Ilizaliturri FJ.
    Clin Cancer Res; 2008 Mar 01; 14(5):1561-70. PubMed ID: 18316581
    [Abstract] [Full Text] [Related]

  • 15. What signals are generated by anti-CD20 antibody therapy?
    Bonavida B.
    Curr Hematol Malig Rep; 2006 Dec 01; 1(4):205-13. PubMed ID: 20425315
    [Abstract] [Full Text] [Related]

  • 16. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab).
    Nishida M, Usuda S, Okabe M, Miyakoda H, Komatsu M, Hanaoka H, Teshigawara K, Niwa O.
    Int J Oncol; 2007 Jul 01; 31(1):29-40. PubMed ID: 17549402
    [Abstract] [Full Text] [Related]

  • 17. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma.
    Tafuku S, Matsuda T, Kawakami H, Tomita M, Yagita H, Mori N.
    Eur J Haematol; 2006 Jan 01; 76(1):64-74. PubMed ID: 16343273
    [Abstract] [Full Text] [Related]

  • 18. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
    Gall JM, Davol PA, Grabert RC, Deaver M, Lum LG.
    Exp Hematol; 2005 Apr 01; 33(4):452-9. PubMed ID: 15781336
    [Abstract] [Full Text] [Related]

  • 19. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
    Smith MR.
    Oncogene; 2003 Oct 20; 22(47):7359-68. PubMed ID: 14576843
    [Abstract] [Full Text] [Related]

  • 20. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance.
    Bannerji R, Kitada S, Flinn IW, Pearson M, Young D, Reed JC, Byrd JC.
    J Clin Oncol; 2003 Apr 15; 21(8):1466-71. PubMed ID: 12697868
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.